Physician profile
Emerson E Harrison
NPI 1225130800
$5,345.61
in general payments reported to CMS, 2019-2025
35 companies · $622 in 2025
The $622 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $146 · 2021: $603 · 2022: $669 · 2023: $817 · 2024: $2,091 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468 · Travel and Lodging: $1,053 · Education: $8.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.48 |
| Travel and Lodging | $1,053.15 |
| Education | $8.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,061.60 | 2024 | |
| Axonics, INC. | $573.76 | 2021-2024 | Axonics |
| Coloplast Corp | $556.17 | 2020-2025 | Titan, Speedicath |
| Astellas Pharma US INC | $487.98 | 2019-2023 | Veozah, Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $383.53 | 2023-2025 | Orgovyx, Gemtesa |
| Endo Pharmaceuticals INC. | $321.37 | 2019-2024 | Xiaflex, Aveed |
| Boston Scientific Corporation | $285.82 | 2021-2025 | Ams 700, Spaceoar Vue System - 10ml, Lumenis Pulse 120h |
| Urogen Pharma, INC. | $212.06 | 2025 | |
| Myovant Sciences INC. | $179.28 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $157.39 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter, Urgent Pc Neuromodulation System |
| Procept Biorobotics Corporation | $143.17 | 2024 | Aquabeam System |
| Tolmar, INC. | $141.02 | 2023-2025 | Eligard, Jatenzo |
| Dendreon Pharmaceuticals LLC | $118.43 | 2019-2025 | Provenge |
| Medtronic, INC. | $91.64 | 2021-2024 | Interstim |
| Teleflex LLC | $91.26 | 2023-2024 | Urolift |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.78 | 2019-2023 | |
| Vertex Pharmaceuticals Incorporated | $53.28 | 2025 | |
| Progenics Pharmaceuticals, INC. | $45.33 | 2022 | |
| Pfizer INC. | $37.79 | 2019 | |
| Palette Life Sciences, INC. | $30.85 | 2022 | |
| Endo USA, INC. | $24.84 | 2024 | Xiaflex |
| Abbvie INC. | $23.91 | 2023 | |
| Daiichi Sankyo INC. | $23.76 | 2022 | |
| Janssen Biotech, INC. | $22.31 | 2019 | |
| Medtronic USA, INC. | $21.60 | 2020 | |
| Blue Earth Diagnostics | $21.13 | 2019 | |
| Olympus America INC. | $19.84 | 2024 | Itind System |
| Merck Sharp & Dohme LLC | $17.50 | 2022 | |
| Conmed Corporation | $17.50 | 2024 | Airseal |
| Kowa Pharmaceuticals America, INC. | $16.15 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.15 | 2025 | Exparel |
| Mimedx Group, INC. | $15.64 | 2024 | |
| Karl Storz Endoscopy-America | $13.77 | 2021 | |
| Travere Therapeutics, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emerson Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.